• Source: Daunorubicin/cytarabine

Daunorubicin/cytarabine, sold under the brand name Vyxeos, is a fixed-dose combination medication used for the treatment of acute myeloid leukemia. It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.




Medical uses


Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.




References

Kata Kunci Pencarian:

• Daunorubicin/cytarabine
• Cytarabine
• Daunorubicin
• 7+3 (chemotherapy)
• Doxorubicin
• Venetoclax
• Idarubicin
• List of chemotherapeutic agents
• Antimetabolite
• Vincristine